Parallel Fluidics, a microfluidics and lab automation specialist, spent the week intensifying commercial outreach for its LNP Screening Array, targeting both conference leads and Boston’s dense biopharma hub. Following an active presence at SLAS 2026, the company is emphasizing that its platform runs on existing liquid-handling systems, reducing the need for new capital equipment.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The firm reported strong engagement with SLAS attendees, including workflow discussions and plans for follow-up demonstrations intended to convert interest into pilot evaluations. For those who did not attend, Parallel Fluidics is encouraging requests for complimentary Starter Arrays, extending its sales funnel and lowering adoption barriers for new users.
In the Boston area, the company is promoting on-site demonstrations of its LNP Screening Array directly on customers’ liquid handlers to showcase automated lipid nanoparticle formulation. These hands-on demos, combined with free Starter Arrays for initial campaigns, are designed to provide low-friction trials and deepen relationships with local biotech and biopharma labs.
Technically, the LNP Screening Array is positioned as a configurable microfluidic platform that supports staggered herringbone, flow focusing, and T-junction mixing geometries to tune particle size and polydispersity index. By automating these mixers on standard liquid-handler decks, the solution targets higher-throughput, more reproducible LNP formulation for mRNA therapeutics and nanoparticle-based drug delivery.
From a financial perspective, the week’s activity underscores an early but deliberate go-to-market push centered on demos, starter kits, and regional focus in a key biotech cluster. While no sales figures were disclosed, increased visibility at SLAS and concentrated outreach in Boston may help Parallel Fluidics build a pipeline of prospective users, support recurring consumables revenue, and strengthen its positioning in the emerging LNP and lab automation markets.
Overall, it was a commercially focused week for Parallel Fluidics, as the company leveraged conference momentum and local on-site demos to drive adoption of its LNP Screening Array and lay groundwork for future growth in RNA-delivery workflows.